Table 4.
Multiple-adjusted HRs for OS by baseline BMI level, stratified by covariates
| Stratification covariate | No. of patients | Underweight (HRa) | Normal weight [HR (95% CI)a] | Overweight/obese [HR (95% CI)a] | P b |
|---|---|---|---|---|---|
| Age (years) | 0.675 | ||||
| <45 | 419 | 1.0 | 1.01 (0.74–1.38) | 0.74 (0.50–1.09) | |
| ≥45 | 400 | 1.0 | 0.76 (0.55–1.06) | 0.54 (0.37–0.79) | |
| Sex | 0.680 | ||||
| Men | 681 | 1.0 | 0.82 (0.64–1.04) | 0.59 (0.44–0.79) | |
| Women | 138 | 1.0 | 1.29 (0.67–2.45) | 0.93 (0.45–1.94) | |
| UICC T category | 0.471 | ||||
| T1–2 | 369 | 1.0 | 0.84 (0.60–1.17) | 0.78 (0.52–1.17) | |
| T3–4 | 450 | 1.0 | 0.88 (0.65–1.19) | 0.49 (0.34–0.70) | |
| UICC N category | 0.501 | ||||
| N0–1 | 417 | 1.0 | 0.83 (0.61–1.14) | 0.55 (0.37–0.82) | |
| N2–3 | 402 | 1.0 | 0.86 (0.60–1.18) | 0.67 (0.46–0.98) | |
| Metastasis onset | 0.551 | ||||
| Synchronous | 272 | 1.0 | 0.94 (0.60–1.49) | 0.55 (0.33–0.90) | |
| Metachronous | 547 | 1.0 | 0.80 (0.62–1.04) | 0.67 (0.48–0.92) | |
| Lung metastasis | 0.761 | ||||
| Absent | 469 | 1.0 | 0.92 (0.69–1.24) | 0.66 (0.46–0.95) | |
| Present | 350 | 1.0 | 0.78 (0.54–1.12) | 0.62 (0.40–0.94) | |
| Liver metastasis | 0.098 | ||||
| Absent | 574 | 1.0 | 0.70 (0.54–0.91) | 0.45 (0.32–0.62) | |
| Present | 245 | 1.0 | 1.39 (0.22–2.19) | 1.46 (0.88–2.43) | |
| Bone metastasis | 0.051 | ||||
| Absent | 382 | 1.0 | 0.83 (0.58–1.18) | 0.76 (0.50–1.14) | |
| Present | 437 | 1.0 | 0.91 (0.68–1.23) | 0.57 (0.39–0.82) | |
| Solitary lesion | 0.062 | ||||
| No | 701 | 1.0 | 0.90 (0.72–1.14) | 0.60 (0.45–0.80) | |
| Yes | 118 | 1.0 | 0.35 (0.14–0.86) | 0.44 (0.17–1.13) | |
| Number of involved sites | 0.331 | ||||
| One | 545 | 1.0 | 0.72 (0.57–0.99) | 0.53 (0.38–0.74) | |
| Two or more | 274 | 1.0 | 1.11 (0.75–1.66) | 0.84 (0.52–1.33) | |
| Treatment modality | 0.055 | ||||
| CT | 607 | 1.0 | 0.92 (0.71–1.19) | 0.56 (0.41–0.77) | |
| CT + LT | 212 | 1.0 | 0.74 (0.46–1.21) | 0.89 (0.52–1.52) | |
OS overall survival; BMI body mass index; UICC Union of International Cancer Control; CT chemotherapy; LT local therapy; HR hazard ratio; CI confidence interval
aAdjusted for age, sex, UICC T category, UICC N category, onset of metastasis, solitary lesion, lung metastasis, liver metastasis, bone metastasis, number of involved sites, and treatment modality, excluding stratification covariate
b P for interaction